Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $0.12 USD
Change Today 0.00 / 0.00%
Volume 0.0
BZYR On Other Exchanges
Symbol
Exchange
OTC US
As of 8:10 PM 08/27/15 All times are local (Market data is delayed by at least 15 minutes).

burzynski research institute (BZYR) Snapshot

Open
$0.12
Previous Close
$0.12
Day High
$0.12
Day Low
$0.12
52 Week High
11/14/14 - $0.22
52 Week Low
08/13/15 - $0.07
Market Cap
15.1M
Average Volume 10 Days
9.1K
EPS TTM
$-0.02
Shares Outstanding
131.4M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for BURZYNSKI RESEARCH INSTITUTE (BZYR)

Related News

No related news articles were found.

burzynski research institute (BZYR) Related Businessweek News

No Related Businessweek News Found

burzynski research institute (BZYR) Details

Burzynski Research Institute, Inc. operates a research and development facility of Antineoplaston drugs being tested for use in the treatment of cancer in the United States. The company focuses on the research, development, production, marketing, promotion, and sale of medical chemical compounds, such as growth-inhibiting peptides, amino acid derivatives, and organic acids. It also provides consulting services. Burzynski Research Institute, Inc. was founded in 1977 and is based in Houston, Texas.

1 Employees
Last Reported Date: 05/29/15
Founded in 1977

burzynski research institute (BZYR) Top Compensated Officers

Chairman, Chief Executive Officer, President,...
Total Annual Compensation: --
Secretary and Treasurer
Total Annual Compensation: --
Vice President of Clinical Trials
Total Annual Compensation: --
Compensation as of Fiscal Year 2015.

burzynski research institute (BZYR) Key Developments

Burzynski Research Institute Announces Publication of Phase II Results in Adults with Recurrent Anaplastic Astrocytoma

Burzynski Research Institute, Inc. announced the publication of data by the Burzynski Clinic on two of the company’s clinical stage products Antineoplaston A10 injections (Atengenal®) and Antineoplaston AS2-1 injections(Astugenal®). Antineoplastons A10 and AS2-1 are synthetic amino acid derivatives. The phase II, single-arm, two-stage, interventional trial was conducted in the United States and evaluated adults with recurrent anaplastic astrocytoma (AA). All patients previously underwent surgery, all received radiation therapy and 59% of patients underwent chemotherapy. The study was closed for admission after enrollment of 27 adults out of a planned 40 patients, as the goal for complete and partial response had been met in five study eligible patients. Progression-free survival (PFS) and overall survival (OS) at 1, 2, 5 and 10 years are presented. The only serious, but reversible, toxicity was Grade 3 hypokalemia in 7% of patients. No chronic toxicities were noted.

Burzynski Research Institute, Inc. Announces Publication of Phase II Results in Adults with Newly-Diagnosed Anaplastic Astrocytoma

Burzynski Research Institute, Inc. announced the publication of data by the Burzynski Clinic on two of the company’s clinical stage products Antineoplaston A10 injections (Atengenal®) and Antineoplaston AS2-1 injections (Astugenal®). Antineoplastons A10 and AS2-1 are synthetic amino acid derivatives. The phase II, single-arm, two-stage, interventional trial was conducted in the United States and evaluated adults with newly-diagnosed anaplastic astrocytoma (AA). The study was closed for admission after enrollment of 19 adults out of a planned 40 patients, as the goal for complete response had been met in four study eligible patients. Progression-free survival (PFS) and overall survival (OS) at 1, 2, 3, 5 and 10 years are presented. A small number of patients experienced serious, but reversible Grade 3 and 4 toxicities, including hypernatremia, hypokalemia and somnolence. No chronic toxicities were noted.

Burzynski Research Institute, Inc. Announces Publication of Phase 2 Clinical Study in Metastatic Colon Adenocarcinoma of the Liver

The Burzynski Research Institute, Inc. (BRI) announced that results of a study independently conducted by the Department of Surgery at Kurume University Medical Center in Japan have been published. The study, a randomized non-blinded phase 2 trial, compared 5-fluorouracil hepatic arterial infusion as post-operative adjuvant therapy with and without Antineoplastons A10/AS2-1 Injections for colorectal metastasis of the liver. A total of 65 patients, with histologically confirmed metastatic colon adenocarcinoma of the liver, were evaluated. Primary endpoints included cancer-specific survival. Secondary endpoints included relapse-free survival, clinical status and extent of recurrence, salvage surgery rate and toxicity. BRI believed that the completion of the study represents an important milestone in the development of Antineoplastons and that further efficacy trials of Antineoplastons in colorectal cancer should continue to be pursued.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BZYR:US $0.12 USD 0.00

BZYR Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for BZYR.
View Industry Companies
 

Industry Analysis

BZYR

Industry Average

Valuation BZYR Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BURZYNSKI RESEARCH INSTITUTE, please visit www.burzynskiclinic.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.